PDF(Pubmed)
Abstract：
UNASSIGNED: To summarize current evidence about the influence of body composition on the prognosis of patients with hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) treatment.
UNASSIGNED: Public databases were systematically searched to identify relevant studies published from the inception of the database up to May 2023. Studies that evaluated the association between body composition and clinical outcomes in HCC patients who underwent TACE were included. A pre-designed table was applied to summarize relevant information. Meta-analysis was performed to estimate the association of body composition with overall survival.
UNASSIGNED: Fourteen studies were included in this review, including 3631 patients (sample size range: 56-908, median 186). All body composition measurements (including skeletal muscle area, visceral and subcutaneous adipose area, and bone mineral density) were based on computer tomography. The commonly used parameter was skeletal muscle index at 3rd lumbar vertebra level (8/14). Three studies evaluated the correlations of body composition changes with the prognosis after TACE. Most studies (12/14) identified body composition parameters as an independent indicator for overall survival, progression-free survival, and treatment response rate. The hazard ratio of different body composition parameters ranged from 1.01 to 2.88, and hazard ratio of body composition changes ranged from 1.88 to 5.93. The pooled hazard ratio of sarcopenia for overall survival was 1.38 (95 %CI: 1.20-1.58).
UNASSIGNED: Body composition seems to be an important prognostic factor for a poorer clinical outcome after TACE treatment in patients with hepatocellular carcinoma. Future prospective studies with a larger sample size are required to confirm these findings.
UNASSIGNED: This study has been prospectively registered at the PROSPERO platform (https://www.crd.york.ac.uk/prospero/) with the registration No. CRD42022345602.
UNASSIGNED: Public databases were systematically searched to identify relevant studies published from the inception of the database up to May 2023. Studies that evaluated the association between body composition and clinical outcomes in HCC patients who underwent TACE were included. A pre-designed table was applied to summarize relevant information. Meta-analysis was performed to estimate the association of body composition with overall survival.
UNASSIGNED: Fourteen studies were included in this review, including 3631 patients (sample size range: 56-908, median 186). All body composition measurements (including skeletal muscle area, visceral and subcutaneous adipose area, and bone mineral density) were based on computer tomography. The commonly used parameter was skeletal muscle index at 3rd lumbar vertebra level (8/14). Three studies evaluated the correlations of body composition changes with the prognosis after TACE. Most studies (12/14) identified body composition parameters as an independent indicator for overall survival, progression-free survival, and treatment response rate. The hazard ratio of different body composition parameters ranged from 1.01 to 2.88, and hazard ratio of body composition changes ranged from 1.88 to 5.93. The pooled hazard ratio of sarcopenia for overall survival was 1.38 (95 %CI: 1.20-1.58).
UNASSIGNED: Body composition seems to be an important prognostic factor for a poorer clinical outcome after TACE treatment in patients with hepatocellular carcinoma. Future prospective studies with a larger sample size are required to confirm these findings.
UNASSIGNED: This study has been prospectively registered at the PROSPERO platform (https://www.crd.york.ac.uk/prospero/) with the registration No. CRD42022345602.
摘要：
■总结目前关于身体成分对肝动脉化疗栓塞（TACE）治疗后肝细胞癌（HCC）患者预后影响的证据。
■对公共数据库进行了系统搜索，以确定从数据库开始到2023年5月发表的相关研究。包括评估接受TACE的HCC患者的身体成分与临床结果之间的关联的研究。应用了预先设计的表格来总结相关信息。进行荟萃分析以评估身体成分与总生存期的关系。
■这篇综述包括14项研究，包括3631名患者（样本量范围：56-908，中位数186）。所有身体成分测量（包括骨骼肌面积，内脏和皮下脂肪面积，和骨矿物质密度）基于计算机断层扫描。常用参数为第3腰椎水平骨骼肌指数(8/14)。三项研究评估了TACE后身体成分变化与预后的相关性。大多数研究（12/14）确定身体成分参数作为总生存的独立指标，无进展生存期,和治疗反应率。不同身体成分参数的风险比范围为1.01至2.88，身体成分变化的风险比范围为1.88至5.93。总生存期的肌少症合并风险比为1.38（95CI：1.20-1.58）。
■身体成分似乎是肝细胞癌患者TACE治疗后临床结局较差的重要预后因素。未来需要更大样本量的前瞻性研究来证实这些发现。
■这项研究已在PROSPERO平台（https://www.crd.约克。AC.uk/prospro/），注册号为CRD42022345602。
■对公共数据库进行了系统搜索，以确定从数据库开始到2023年5月发表的相关研究。包括评估接受TACE的HCC患者的身体成分与临床结果之间的关联的研究。应用了预先设计的表格来总结相关信息。进行荟萃分析以评估身体成分与总生存期的关系。
■这篇综述包括14项研究，包括3631名患者（样本量范围：56-908，中位数186）。所有身体成分测量（包括骨骼肌面积，内脏和皮下脂肪面积，和骨矿物质密度）基于计算机断层扫描。常用参数为第3腰椎水平骨骼肌指数(8/14)。三项研究评估了TACE后身体成分变化与预后的相关性。大多数研究（12/14）确定身体成分参数作为总生存的独立指标，无进展生存期,和治疗反应率。不同身体成分参数的风险比范围为1.01至2.88，身体成分变化的风险比范围为1.88至5.93。总生存期的肌少症合并风险比为1.38（95CI：1.20-1.58）。
■身体成分似乎是肝细胞癌患者TACE治疗后临床结局较差的重要预后因素。未来需要更大样本量的前瞻性研究来证实这些发现。
■这项研究已在PROSPERO平台（https://www.crd.约克。AC.uk/prospro/），注册号为CRD42022345602。
